Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression.

ABSTRACT:

Background

Ovarian cancer is the most fatal gynecologic malignancy worldwide due to its vagueness, delay in diagnosis, recurrence, and drug resistance. Therefore, a new type of ovarian cancer treatment prediction biomarker is urgently needed to supplement existing tools. A total of 230 people participated in this study. Out of this figure, 100 participants were patients who underwent an ovarian tumor operation, another 100 participants were ovarian benign patients, and the remaining 30 participants were healthy women. Cancer (experimental) group were 100 patients who underwent ovarian tumor operation, while the control groups were 130 participants consisting of 100 ovarian benign patients and 30 healthy women. Levels of SAA, carbohydrate antigen-125 (CA-125), and human epididymis p

SUBMITTER: Li Z 

PROVIDER: S-EPMC7285470 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature